Unifarma Herbals Ashwagandha Pharma Grade API is not inherently free-flowing; typical lots of spray-dried or vacuum-dried extract exhibit a bulk density of 0.35–0.52 g/mL and tapped density of 0.55–0.78 g/mL, yielding a Carr index in the range 27–38 when calculated from USP <616>. Direct compression is therefore confined to formulations where the extract load is not more than 40–45% w/w of the tablet core and where forced sieving through a 600 µm screen precedes blending. A process route on a rotary tablet press with 16–27 stations typically requires a precompression force of 2–4 kN and main compression force of 10–20 kN to obtain tablet breaking force of 70–110 N measured by USP <1217>; friability remains below 1.0% w/w per USP <1216> when the granulate or direct compression blend has residual moisture below 4.0% w/w and the compression environment is maintained at 20–24 °C and 35–45% RH. The blend is prepared by first passing the API through a 0.6 mm screen, then mixing with microcrystalline cellulose and pregelatinised starch for 10–15 min in a bin blender at 15–25 rpm, adding 0.5% w/w magnesium stearate and 2.0% w/w colloidal silicon dioxide in a final lubricant cycle not exceeding 3 min. Over-lubrication beyond 5 min or 1.0% w/w magnesium stearate is avoided because it lowers tablet tensile strength and delays disintegration beyond 15 min measured by USP <701> in deionised water at 37 ± 2 °C. Dissolution testing per USP <711> Apparatus II at 50 rpm in 900 mL of pH 6.8 phosphate buffer containing 0.5% w/v sodium lauryl sulfate is used as a product-specific control because withanolide glycosides show pH-dependent solubility. Published data for direct compression formulations of this specific API are limited; therefore, the compression window should be confirmed with at least three active lots covering the low, mid, and high ranges of tapped density.

What Restricts Weight Uniformity During High-Speed Capsule Filling of Low-Dose Withanolide Blends?

Capsule filling of low-dose granulates is dominated by powder flow and in-die densification. The API has low bulk density and high hygroscopicity; unmodified dry extract in a dosator-type capsule machine at speeds above 10,000 capsules/h tends to produce fill weight variation greater than 4–6% RSD, especially when the target fill weight is below 250 mg. Tamping-pin machines with 5–6 dosing stations are preferred because they allow densification to a plug density of 0.70–0.85 g/mL before ejection. The powder for encapsulation is densified either by slugging or by roller compaction to a Hausner ratio below 1.25. A granulate with 0.3–0.5% w/w magnesium stearate and 0.5–1.0% w/w colloidal silicon dioxide is filled into size 0 or size 1 hard gelatin capsules at 18–22 °C and 35–45% RH; higher relative humidity increases shell brittleness in gelatin capsules and may raise granulate moisture above 5% w/w, causing sticking on the dosing disk. HPMC capsules are specified when capsule fill weight variation must remain below 2.0% RSD after 24 h at 25 °C/60% RH, because the HPMC shell equilibrates at a lower moisture content than gelatin under those conditions. Uniformity of dosage units is evaluated by USP <905>; the acceptance value is based on the withanolide assay, not on total capsule weight alone. If the active content per capsule is 125 mg of extract and the total fill weight is 300 mg, the blend must show particle size distribution with D90 below 400 µm by laser diffraction per USP <429> to avoid segregation in the hopper. Capsule disintegration is measured by USP <701> for immediate-release capsules, with a limit of 30 min in 0.1 N HCl at 37 ± 2 °C unless a delayed-release claim is filed.

When the API fraction exceeds 40% w/w of the tablet core, direct compression is replaced by high-shear wet granulation or roller compaction. The granulation vehicle is an aqueous binder solution containing 3–5% w/w povidone K-30 or a hydroalcoholic solution when API moisture sensitivity is critical. Aqueous granulation is performed in a 10 L or 25 L high-shear mixer with impeller speed 200–400 rpm and chopper speed 1500–2500 rpm; wet massing time is limited to 2–5 min because excessive wet massing increases the proportion of fines below 74 µm after drying and reduces granule compressibility. The wet mass is dried in a fluid-bed dryer with inlet air at 45–55 °C and product temperature maintained below 40 °C to minimise withaferin A degradation. Drying continues until loss on drying by USP <731> is 2.5–4.0% w/w; granules are then screened through a 1.0 mm sieve to remove oversize material. The dried granule should have bulk density 0.45–0.60 g/mL, tapped density 0.55–0.75 g/mL, and a Carr index below 25 before tableting. When roller compaction is preferred, the API is preblended with microcrystalline cellulose and crospovidone, then compacted at roll pressure 20–40 bar and milled to a granule fraction passing 1000 µm but retained on 150 µm. Granule moisture above 4.0% w/w causes picking and lamination during compression, while moisture below 2.0% w/w may increase friability and cap hardness. The final blend is lubricated with 0.5% w/w sodium stearyl fumarate when magnesium stearate compatibility with acidic or hygroscopic granulate is questioned.

Oral Suspension Stabilization Is Governed by Flocculation and Low-Shear Viscosity

For oral suspensions, the API is milled or micronised to a D90 below 100 µm, then dispersed in a vehicle containing xanthan gum at 0.2–0.4% w/v or a co-processed microcrystalline cellulose–carboxymethylcellulose sodium at 1.0–2.0% w/v. A wetting agent is required because the extract contains poorly wettable lipophilic withanolides; polysorbate 80 at 0.05–0.2% w/v is incorporated before adding the suspending agent. The pH is buffered between 4.5 and 6.0 with citrate or phosphate buffers because alkaline pH accelerates lactone ring opening in withaferin A and may reduce potency. Flocculation is controlled by adjusting ionic strength and by avoiding excessive anionic polymer concentrations that produce irreversible sedimentation; the final suspension is specified with apparent viscosity of 150–400 mPa·s at 25 °C using a Brookfield spindle at 10 rpm. Preservative systems consist of methylparaben 0.18% w/v and propylparaben 0.02% w/v or potassium sorbate 0.1% w/v, with antimicrobial effectiveness tested per USP <51>. The product is filled under continuous agitation to maintain homogeneity; resuspendability after 72 h sedimentation is measured by shaking not more than 15 s and assaying top, middle, and bottom samples for withanolide content. Published data for suspension stability of Ashwagandha extract are limited; a product-specific method with USP <711> Apparatus II at 25 rpm is generally required because the higher viscosity of the vehicle can under- or overestimate release compared with tablet dosage forms.

Parenteral Vehicle Engineering and Sterile Filtration Boundaries for Withaferin A–Rich Extracts

Parenteral administration of Withania somnifera extract is the most constrained downstream application. The API is not freely soluble in water; withaferin A and related withanolides require a solubilising vehicle such as hydroxypropyl betadex 10–20% w/v in a mixed aqueous system, or a co-solvent platform of propylene glycol and polyethylene glycol 400 below 30% w/v combined with pH adjustment to 6.0–7.0. Direct aqueous injection without solubility enhancement is not supported by monograph data. Terminal steam sterilisation at 121 °C for 15 min is often contraindicated because withaferin A is heat labile; thus aseptic processing with filtration through a 0.45 µm prefilter followed by a 0.22 µm sterilising-grade membrane is used, provided the formulation does not form micellar aggregates larger than the membrane pore size. If aggregation occurs, the filter may remove withanolides and reduce assay below the release limit. Sterility is verified per USP <71>; bacterial endotoxin limit is calculated from the maximum dose per USP <85>. For a parenteral dose of 10 mg/kg, the limit is 0.5 EU/mg; for 100 mg/kg, it is 0.05 EU/mg. Particulate matter must comply with USP <788> for small-volume injections, and subvisible particulate matter is evaluated by USP <787> for products intended for intravenous use. Elemental impurities are controlled by ICH Q3D and USP <232>/<233>, while residual solvents from co-solvent vehicles must meet ICH Q3C limits. Intramuscular injection may tolerate a higher particulate burden, but intravenous administration must meet the strict subvisible particle thresholds. Published stability data for this specific API in sterile parenteral vehicles are limited; therefore, forced degradation studies under ICH Q1A(R2) conditions are required before a terminal sterilisation or aseptic process is locked.

Unit-dose sachet granulation transfers the upstream drying burden to the packaging barrier. Unit-dose sachets containing 1.0–2.0 g of reconstitutable granulate are manufactured by dry granulation to avoid residual moisture above 2.5% w/w. The granulate is sized through 16–60 mesh screens and packed in foil laminate sachets with water vapour transmission rate below 0.05 g/m²/24 h at 38 °C/90% RH if the product contains hygroscopic ashwagandha extract. The reconstitution vehicle may be plain water; the granulate must disperse without lumping within 60 s under manual swirling. Therefore, a disintegrant such as crospovidone 2–3% w/w or croscarmellose sodium 1–2% w/w is incorporated to prevent clumping. The dry granulate blend includes a sweetener and a flow aid; the final moisture content is checked by USP <731> and water activity by a dew-point instrument. If water activity exceeds 0.6 Aw, the product is held for further drying before packaging. Granule flow is not critical for sachet filling when using auger volumetric fillers, but bulk density variation must be controlled within ±5% RSD to maintain fill weight uniformity. The sachet product is tested for deliverable mass and content uniformity by USP <905>, and for microbial quality by USP <61> and USP <62>.

If the Granulate Is Destined for Effervescent Reconstitution, Water Activity and Acid–Carbonate Ratios Must Be Fixed

Effervescent dosage forms containing Ashwagandha extract demand strict moisture control because the acid–carbonate pair reacts in the presence of residual water. The formulation consists of citric acid or tartaric acid and sodium bicarbonate in a stoichiometric ratio that yields pH 4.5–5.5 after complete reaction; the carbonate is adjusted for the extract’s weakly acidic groups. Granulation is performed by melt fusion or by anhydrous ethanol granulation; water is not used. The final granulate must have loss on drying below 1.0% w/w and water activity below 0.30 Aw at 25 °C. Compression is carried out at 20–25 °C and below 30% RH; tablet hardness is maintained at 50–80 N to permit disintegration in 100 mL of water within 3 min without the need for mechanical stirring. Packaging is aluminium tube or desiccant-containing closure because moisture ingress above 0.3% w/w causes premature reaction and loss of product integrity. Published formulation data for ashwagandha effervescent tablets are limited; therefore, the acid–carbonate ratio and drying endpoints should be confirmed by microcalorimetry or water activity mapping before scale-up.